BRPI0407907A - derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos - Google Patents

derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos

Info

Publication number
BRPI0407907A
BRPI0407907A BRPI0407907-8A BRPI0407907A BRPI0407907A BR PI0407907 A BRPI0407907 A BR PI0407907A BR PI0407907 A BRPI0407907 A BR PI0407907A BR PI0407907 A BRPI0407907 A BR PI0407907A
Authority
BR
Brazil
Prior art keywords
processes
acid derivatives
cycloalkyl substituted
medicines
preparing
Prior art date
Application number
BRPI0407907-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Christian Stapper
Stefanie Keil
Heiner Glombik
Eugen Falk
Jochen Goerlitzer
Dirk Gretzke
Hans-Ludwig Schaefer
Wolfgang Wendler
Original Assignee
Aventis Pharma Deustschland Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deustschland Gm filed Critical Aventis Pharma Deustschland Gm
Publication of BRPI0407907A publication Critical patent/BRPI0407907A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
BRPI0407907-8A 2003-02-27 2004-02-19 derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos BRPI0407907A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
BRPI0407907A true BRPI0407907A (pt) 2006-02-14

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0407907-8A BRPI0407907A (pt) 2003-02-27 2004-02-19 derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
BRPI0407758-0A BRPI0407758A (pt) 2003-02-27 2004-02-19 derivados de 3-(2-fenil-oxazol-4-ilmetóxi)-ciclohexilmetóxi-acético e compostos afins como modula-dores de ppar para o tratamento de diabetes do tipo 2 e aterosclerose.
BRPI0407814-4A BRPI0407814A (pt) 2003-02-27 2004-02-19 derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose

Family Applications After (2)

Application Number Title Priority Date Filing Date
BRPI0407758-0A BRPI0407758A (pt) 2003-02-27 2004-02-19 derivados de 3-(2-fenil-oxazol-4-ilmetóxi)-ciclohexilmetóxi-acético e compostos afins como modula-dores de ppar para o tratamento de diabetes do tipo 2 e aterosclerose.
BRPI0407814-4A BRPI0407814A (pt) 2003-02-27 2004-02-19 derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexonaca rbonil-amino)-butìrico e compostos afins como moduladores ppar para o tratamento do diabetes tipo 2 e aterosclerose

Country Status (34)

Country Link
US (5) US7365084B2 (US07259177-20070821-C00095.png)
EP (3) EP1599455B1 (US07259177-20070821-C00095.png)
JP (3) JP2006519193A (US07259177-20070821-C00095.png)
KR (3) KR20050105492A (US07259177-20070821-C00095.png)
CN (3) CN100439347C (US07259177-20070821-C00095.png)
AR (3) AR043432A1 (US07259177-20070821-C00095.png)
AT (3) ATE430738T1 (US07259177-20070821-C00095.png)
AU (3) AU2004215673B2 (US07259177-20070821-C00095.png)
BR (3) BRPI0407907A (US07259177-20070821-C00095.png)
CA (3) CA2517381A1 (US07259177-20070821-C00095.png)
CL (2) CL2004000391A1 (US07259177-20070821-C00095.png)
CO (2) CO5690580A2 (US07259177-20070821-C00095.png)
DE (4) DE10308355A1 (US07259177-20070821-C00095.png)
DK (3) DK1599452T3 (US07259177-20070821-C00095.png)
EC (2) ECSP055986A (US07259177-20070821-C00095.png)
ES (3) ES2329366T3 (US07259177-20070821-C00095.png)
HR (3) HRP20050743A2 (US07259177-20070821-C00095.png)
IL (2) IL170314A (US07259177-20070821-C00095.png)
MA (3) MA27742A1 (US07259177-20070821-C00095.png)
MX (3) MXPA05008988A (US07259177-20070821-C00095.png)
NO (3) NO20054398L (US07259177-20070821-C00095.png)
OA (2) OA13035A (US07259177-20070821-C00095.png)
PA (1) PA8596801A1 (US07259177-20070821-C00095.png)
PE (3) PE20050292A1 (US07259177-20070821-C00095.png)
PL (3) PL378437A1 (US07259177-20070821-C00095.png)
PT (3) PT1599453E (US07259177-20070821-C00095.png)
RS (1) RS20050594A (US07259177-20070821-C00095.png)
RU (3) RU2005129995A (US07259177-20070821-C00095.png)
SA (1) SA04250153A (US07259177-20070821-C00095.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00095.png)
TW (3) TW200500349A (US07259177-20070821-C00095.png)
UY (2) UY28209A1 (US07259177-20070821-C00095.png)
WO (3) WO2004076427A1 (US07259177-20070821-C00095.png)
ZA (2) ZA200505768B (US07259177-20070821-C00095.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
AU2006347121B2 (en) 2006-08-10 2013-06-06 Acacia-No-Ki Co., Ltd. Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia
EP2181087B1 (en) 2007-08-16 2015-10-14 Solvay Sa Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
JP5440490B2 (ja) 2008-02-29 2014-03-12 日産化学工業株式会社 チオフェン化合物及びその中間体の製造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116184783A (zh) 2017-12-13 2023-05-30 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
KR19990077319A (ko) 1996-01-17 1999-10-25 한센 핀 베네드, 안네 제헤르 축합된 1,2,4-티아디아진 및 축합된 1,4-티아진 유도체, 그것의제조방법 및 사용
ATE356830T1 (de) 1996-08-30 2007-04-15 Novo Nordisk As Glp-1 derivate
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
PL192664B1 (pl) 1996-12-31 2006-11-30 Reddys Lab Ltd Dr Pochodne azolidynodionu, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne, ich zastosowanie w leczeniu cukrzycy i związanych z nią chorób oraz związki pośrednie
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
AU5443499A (en) * 1998-08-27 2000-03-21 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU782404B2 (en) * 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
EE200100556A (et) 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
CA2378878A1 (en) 1999-07-29 2001-02-08 Jeffrey Thomas Mullaney Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
IL148148A0 (en) * 1999-09-01 2002-09-12 Aventis Pharma Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
ES2215769T3 (es) 1999-12-03 2004-10-16 Astrazeneca Ab Forma cristalina de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico.
KR20080067009A (ko) 2000-03-31 2008-07-17 프로시디온 리미티드 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
EA004244B1 (ru) 2000-04-25 2004-02-26 Киорин Фармасьютикал Ко., Лтд. Новый стабильный кристалл производного тиазолидиндиона и способ его получения
KR100502876B1 (ko) 2000-04-28 2005-07-21 아사히 가세이 파마 가부시키가이샤 신규 이환성 화합물
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
KR20030007934A (ko) * 2000-06-09 2003-01-23 아벤티스 파마 도이칠란트 게엠베하 아실페닐 우레아 유도체, 이의 제조방법 및 약제로서의이의 용도
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
US6930120B2 (en) * 2000-08-23 2005-08-16 Eli Lilly And Company Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
SK7822003A3 (en) 2000-12-21 2003-12-02 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
EP1726586A1 (en) * 2000-12-25 2006-11-29 Ono Pharmaceutical Co., Ltd. Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
JP2004529097A (ja) * 2001-02-15 2004-09-24 ファイザー・プロダクツ・インク Pparアゴニスト
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CA2448552A1 (en) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
EP1425014B1 (de) 2001-08-31 2006-12-13 Sanofi-Aventis Deutschland GmbH Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren
DE60327922D1 (de) 2002-02-05 2009-07-23 Lilly Co Eli Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
TNSN05204A1 (en) 2007-06-11
AU2004215677A1 (en) 2004-09-10
WO2004076426A1 (de) 2004-09-10
AR043427A1 (es) 2005-07-27
RU2005129995A (ru) 2006-01-27
ES2287700T3 (es) 2007-12-16
US20080015238A1 (en) 2008-01-17
MXPA05008995A (es) 2005-10-18
TW200508210A (en) 2005-03-01
ZA200505768B (en) 2005-11-23
DK1599453T3 (da) 2009-08-24
JP2006519193A (ja) 2006-08-24
TW200510352A (en) 2005-03-16
ATE435217T1 (de) 2009-07-15
TW200500349A (en) 2005-01-01
JP2006519199A (ja) 2006-08-24
EP1599452B1 (de) 2007-06-20
BRPI0407758A (pt) 2006-02-14
AU2004215672A1 (en) 2004-09-10
CN1753881A (zh) 2006-03-29
CO5690578A2 (es) 2006-10-31
PL378130A1 (pl) 2006-03-06
AU2004215673B2 (en) 2009-10-01
AR043432A1 (es) 2005-07-27
AU2004215673A1 (en) 2004-09-10
US7872034B2 (en) 2011-01-18
US7335671B2 (en) 2008-02-26
RS20050594A (en) 2007-12-31
NO20054408D0 (no) 2005-09-22
CN100439345C (zh) 2008-12-03
ATE365159T1 (de) 2007-07-15
PE20050293A1 (es) 2005-05-24
ECSP055985A (es) 2006-01-16
ZA200505765B (en) 2006-05-31
EP1599455B1 (de) 2009-07-01
PL378437A1 (pl) 2006-04-03
DE502004009690D1 (de) 2009-08-13
CA2517386A1 (en) 2004-09-10
JP2006519194A (ja) 2006-08-24
WO2004076428A1 (de) 2004-09-10
KR20050106462A (ko) 2005-11-09
SA04250153A (ar) 2005-12-03
EP1599455A1 (de) 2005-11-30
CN100398526C (zh) 2008-07-02
UY28209A1 (es) 2004-09-30
MXPA05008988A (es) 2005-10-18
AU2004215677B2 (en) 2010-01-07
US20040209920A1 (en) 2004-10-21
CL2004000391A1 (es) 2005-01-07
MA27742A1 (fr) 2006-02-01
ES2326418T3 (es) 2009-10-09
US20080167354A1 (en) 2008-07-10
NO20054396D0 (no) 2005-09-22
PT1599452E (pt) 2007-09-12
MA27736A1 (fr) 2006-02-01
DK1599452T3 (da) 2007-10-01
RU2005130002A (ru) 2006-01-27
AR043433A1 (es) 2005-07-27
OA13034A (en) 2006-11-10
PE20050292A1 (es) 2005-05-24
PT1599453E (pt) 2009-07-14
IL170314A (en) 2010-11-30
ES2329366T3 (es) 2009-11-25
US7259177B2 (en) 2007-08-21
AU2004215672B2 (en) 2010-01-07
UY28210A1 (es) 2004-09-30
DK1599455T3 (da) 2009-11-09
WO2004076427A1 (de) 2004-09-10
CN1753879A (zh) 2006-03-29
NO20054396L (no) 2005-11-11
HRP20050742A2 (en) 2006-09-30
EP1599453A1 (de) 2005-11-30
KR20050106461A (ko) 2005-11-09
EP1599453B1 (de) 2009-05-06
PT1599455E (pt) 2009-09-29
BRPI0407814A (pt) 2006-02-14
NO20054398D0 (no) 2005-09-22
CN1756748A (zh) 2006-04-05
CA2517381A1 (en) 2004-09-10
ATE430738T1 (de) 2009-05-15
US20050215596A1 (en) 2005-09-29
DE502004004139D1 (de) 2007-08-02
RU2005129992A (ru) 2006-02-10
CA2516620A1 (en) 2004-09-10
PL377735A1 (pl) 2006-02-20
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
MA27737A1 (fr) 2006-02-01
ECSP055986A (es) 2006-01-16
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
KR20050105492A (ko) 2005-11-04
PE20040959A1 (es) 2005-01-17
DE502004009453D1 (de) 2009-06-18
EP1599452A1 (de) 2005-11-30
CN100439347C (zh) 2008-12-03
US7365084B2 (en) 2008-04-29
US20050101637A1 (en) 2005-05-12
OA13035A (en) 2006-11-10
HRP20050744A2 (en) 2006-09-30
DE10308355A1 (de) 2004-12-23
NO20054398L (no) 2005-11-02
CL2004000392A1 (es) 2005-04-22
CO5690580A2 (es) 2006-10-31
MXPA05008951A (es) 2005-11-04
TNSN05206A1 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
BRPI0514310A (pt) 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BRPI0407907A (pt) derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BRPI0507309A (pt) derivados de ácido 7-fenilamino-4quinolon-3-carboxìlico, processos para produção e seu uso como medicamento
BRPI0513086A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos
BRPI0515168A (pt) 7-azaindóis, processos para sua preparação e seu uso como fármacos
BRPI0407504A (pt) heterociclos n-arila substituìdo, processo para sua preparação e uso dos mesmos como medicamentos
BR0312697A (pt) Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
BRPI0510770A (pt) derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso
BR0013727A (pt) Derivados de sulfonilcarboxamida, processo para sua preparação e seu uso como medicamento
BR0210008A (pt) Derivados de feniluréia substituìdos com carboxamida, processos para produção dos mesmos como medicamentos
BRPI0514679A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição
BRPI0407901A (pt) derivados de diarilcicloalquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
UY26332A1 (es) Nuevos derivados del ácido aminodicarboxílico con propiedades farmacéuticas.
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
BR0307291A (pt) Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; método para o tratamento e profilaxia de distúrbios diversos e de obesidade em um humano
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
BR0114092A (pt) Guanididas de ácido cinámico substituìdas, processos para a sua preparação, sua aplicação como medicamento bem como o medicamento contendo as mesmas
BRPI0517792A (pt) macrolonas - quinolonas amino-substituìdas
BR0015322A (pt) Derivados de indeno-, nafto- e benzociclohepta-dihidrotiazol, sua preparação e seu emprego como medicamentos anoréticos
BR0311896A (pt) Difenilazetidinonas substituìdas com grupos ácidos, processo para sua preparação, medicamentos contendo estes compostos e seu uso
BRPI0507321A (pt) derivados de 7-amino-4-quinolona-3-ácido carboxìlico substituìdos com cicloalquila, processos para produção dos mesmos e uso dos mesmos como medicamento

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.